ALSO NOTED: Dyadic CEO on leave as company probes operations; Singulair OK'd for new condition; and much more...

> The CEO and chairman of Dyadic International, Mark A. Emalfarb, has gone on leave as the company announced it is investigating potential financial improprieties in its operations in China. Release

> The FDA has issued an approvable letter for Wyeth's osteoporosis drug Viviant. Final approval is contingent on a final review of new data from a recently completed late-stage trial. Release

> Wyeth and the Irish government have announced a joint $32 million project to improve the drug developer's R&D operations. Report

> Merck's Singulair has been approved for exercise-induced asthma. Release

> Sciele Pharma is buying Alliant Pharmaceuticals, a pediatric specialty pharma company, for $122 million. Release

> Bavarian Nordic has received an order for 20 million doses of its smallpox vaccine from the U.S. government. Report

> Paladin Labs is buying BioEnvelope for $1.9 million. Paladin gains BioEnvelop's rapidly dissolving film strip technology. Report

> A researcher at Purdue University laboratory is working on a compound that he says could become the first treatment available for Alzheimer's. Report

> A Johns Hopkins University research team has developed a synthetic drug based on a Chinese herbal folk remedy that cured malaria-infected mice with a single shot. Report

And Finally... A new study indicates that migraines may actually help prevent people from suffering memory loss. Report